RESUMEN
The current study was designed to characterize methicillin-resistant Staphylococcus aureus (MRSA) isolated from bovine milk, along with its response to antibiotics, and ultimately reverse its mechanism of resistance by modulation with non-antibiotics. The synergistic combination of antibiotics with NSAIDs were tested in-vivo by giving MRSA challenge to rabbits. The current study reported an overall 23.79% prevalence of MRSA. The BLAST alignment of current study sequences revealed 99% similarity with mecA gene of MRSA from NCBI database. The current study isolates were more similar to each other and also with reference sequences as compared to other mecA gene sequences from Turkey, India, and Russia. Antibiogram of MRSA isolates showed a highly resistant response to cefoxitin, amoxicillin, and gentamicin. Amoxicillin, gentamicin, tylosin, vancomycin, and ciprofloxacin elicited a significant response (p < 0.05) in combination with non-antibiotics against tested MRSA isolates. The highest zone of inhibition (ZOI) increase was noted for vancomycin in combination with flunixin meglumine (145.45%) and meloxicam (139.36%); gentamicin with flunixin meglumine (85.71%) and ciprofloxacin with ivermectin (71.13%). Synergistic behavior was observed in the combination of gentamicin with ketoprofen; sulfamethoxazole and oxytetracycline with meloxicam. Hematological analysis showed significant differences (p < 0.05) among lymphocyte count and bilirubin. On histopathological examination of skin tissue, hyperplasia of epithelium, sloughed off epidermis, hyperkeratosis, infiltration of inflammatory cells, and hemorrhages were observed. The highest cure rate was observed in case of gentamicin in combination with ketoprofen as compared to other treatment groups. The current study concluded antibiotics in combination with non-antibiotics as potential therapeutic agents for resistance modulation against MRSA. This study will help to devise treatment and control strategies against bovine mastitis. Although the prospect of using NSAIDs to manage infections caused by MRSA appears to be a promising direction, further studies should be conducted to test these medications using suitable in-vivo models in controlled clinical trials to justify their repurposing as a treatment for MRSA infections.
Asunto(s)
Cetoprofeno , Mastitis Bovina , Staphylococcus aureus Resistente a Meticilina , Oxitetraciclina , Infecciones Estafilocócicas , Amoxicilina/uso terapéutico , Animales , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Antiinflamatorios no Esteroideos , Bilirrubina/uso terapéutico , Bovinos , Cefoxitina/uso terapéutico , Ciprofloxacina/farmacología , Ciprofloxacina/uso terapéutico , Reposicionamiento de Medicamentos , Femenino , Gentamicinas/farmacología , Gentamicinas/uso terapéutico , Ivermectina/uso terapéutico , Cetoprofeno/uso terapéutico , Mastitis Bovina/tratamiento farmacológico , Meloxicam/uso terapéutico , Pruebas de Sensibilidad Microbiana , Conejos , Infecciones Estafilocócicas/tratamiento farmacológico , Infecciones Estafilocócicas/epidemiología , Infecciones Estafilocócicas/veterinaria , Sulfametoxazol , Tilosina/uso terapéutico , VancomicinaRESUMEN
This study evaluated a battery of pain-stimulated, pain-depressed, and pain-independent behaviors for preclinical pharmacological assessment of candidate analgesics in mice. Intraperitoneal injection of dilute lactic acid (IP acid) served as an acute visceral noxious stimulus to produce four pain-related behaviors in male and female ICR mice: stimulation of 1) stretching, 2) facial grimace, 3) depression of rearing, and 4) depression of nesting. Additionally, nesting and locomotion in the absence of the noxious stimulus were used to assess pain-independent drug effects. These six behaviors were used to compare effects of two mechanistically distinct but clinically effective positive controls (ketoprofen and oxycodone) and two negative controls that are not clinically approved as analgesics but produce either general motor depression (diazepam) or motor stimulation (amphetamine). We predicted that analgesics would alleviate all IP acid effects at doses that did not alter pain-independent behaviors, whereas negative controls would not. Consistent with this prediction, ketoprofen (0.1-32 mg/kg) produced the expected analgesic profile, whereas oxycodone (0.32-3.2 mg/kg) alleviated all IP acid effects except depression of rearing at doses lower than those that altered pain-independent behaviors. For the negative controls, diazepam (1-10 mg/kg) failed to block IP acid-induced depression of either rearing or nesting and only decreased IP acid-stimulated behaviors at doses that also decreased pain-independent behaviors. Amphetamine (0.32-3.2 mg/kg) alleviated all IP acid effects but only at doses that also stimulated locomotion. These results support utility of this model as a framework to evaluate candidate-analgesic effects in a battery of complementary pain-stimulated, pain-depressed, and pain-independent behavioral endpoints. SIGNIFICANCE STATEMENT: Preclinical assays of pain and analgesia often yield false-positive effects with candidate analgesics. This study used two positive-control analgesics (ketoprofen, oxycodone) and two active negative controls (diazepam, amphetamine) to validate a strategy for distinguishing analgesics from nonanalgesics by profiling drug effects in a battery of complementary pain-stimulated, pain-depressed, and pain-independent behaviors in male and female mice.
Asunto(s)
Analgésicos/toxicidad , Conducta Animal , Movimiento , Dolor/tratamiento farmacológico , Anfetamina/administración & dosificación , Anfetamina/uso terapéutico , Anfetamina/toxicidad , Analgésicos/administración & dosificación , Analgésicos/uso terapéutico , Animales , Diazepam/administración & dosificación , Diazepam/uso terapéutico , Diazepam/toxicidad , Evaluación Preclínica de Medicamentos/métodos , Evaluación Preclínica de Medicamentos/normas , Reacciones Falso Negativas , Femenino , Cetoprofeno/administración & dosificación , Cetoprofeno/uso terapéutico , Cetoprofeno/toxicidad , Masculino , Ratones , Ratones Endogámicos ICR , Nivel sin Efectos Adversos Observados , Oxicodona/administración & dosificación , Oxicodona/uso terapéutico , Oxicodona/toxicidadRESUMEN
AIM: Low back pain (LBP) is a common musculoskeletal complaint among emergency department (ED) admissions. In this study, it was aimed to compare the effectiveness of systemic treatment with intradermal sterile water injection (ISWI) treatment protocol combined with systemic therapy in patients with LBP of unclear chronicity. METHODS: A prospective randomized, unblinded, controlled clinical study was conducted on patients admitted to the ED for LBP of unclear chronicity. One hundred twelve patients were randomly assigned to two groups; Group ISWI (n = 56) administered ISWI in the LBP region of patients along with systemic intravenous dexketoprofen therapy, while the other group (n = 56) received only systemic intravenous dexketoprofen therapy. The treatment methods' effectiveness was compared by measuring the pain intensity with the Visual Analog Scale (VAS) at admission, 10th minutes, 20th minutes, 30th minutes, and 24 h later. Also, opioid and analgesic consumptions in 24 h after treatment and patient satisfactions were compared. RESULTS: In the treatment of LBP, ISWI treatment was found to be more effective in relieving pain than systemic therapy alone (p < 0.001). Also, it was observed that opioid consumption in the ED and analgesic consumption within 24 h after treatments were decreased in the ISWI group (p < 0.001). The patient satisfaction in the ED was statistically increased (p < 0.001). DISCUSSION: In this unblinded study, ISWI with systemic therapy improved pain outcomes more than systemic therapy alone. Further research is needed to determine whether this was due entirely to placebo effect.
Asunto(s)
Antiinflamatorios no Esteroideos/uso terapéutico , Servicio de Urgencia en Hospital , Cetoprofeno/análogos & derivados , Dolor de la Región Lumbar/terapia , Manejo del Dolor/métodos , Trometamina/uso terapéutico , Agua/administración & dosificación , Adulto , Analgésicos no Narcóticos/uso terapéutico , Analgésicos Opioides/uso terapéutico , Antiinflamatorios no Esteroideos/efectos adversos , Femenino , Humanos , Inyecciones Intradérmicas , Cetoprofeno/efectos adversos , Cetoprofeno/uso terapéutico , Masculino , Persona de Mediana Edad , Dimensión del Dolor , Satisfacción del Paciente , Estudios Prospectivos , Trometamina/efectos adversos , Agua/efectos adversosRESUMEN
INTRODUCTION: Musculoskeletal pain such as low back pain (LBP) are routinely encountered in the ED and contribute to ED overcrowding. The aim of our study was to compare the efficiency of mesotherapy with systemic therapy in pain control in patients with lumbar disk herniation. METHODS: We conducted this prospective parallel randomized controlled trial with the patients admitted to the emergency department with low back pain related to herniated lumbar disk. Mesotherapy was performed to one group, while intravenous dexketoprofen was administered to the control group. Changes in pain intensity at 15th minute, 30th minute, 60th minute and 24th hours after treatment using Visual Analogue Scale (VAS), need to use analgesic drug within 24 h after treatment, and adverse effect of the treatment methods were compared between groups. RESULTS: The decreases in pain intensity were statistically significantly higher in mesotherapy group for all time intervals. The need to use analgesics was statistically significantly three fold higher in the systemic therapy group. There was no statistically significant difference in having any adverse effect between study groups during one-week follow-up period. CONCLUSIONS: Changes in medical practices, from the systemic administration of NSAIDs to the minimally invasive techniques such as mesotherapy with potent efficacy and minimal side effects, may enhance the ability of EDs to meet the waiting time targets and improve patient's satisfaction.
Asunto(s)
Anestésicos Locales/uso terapéutico , Antiinflamatorios no Esteroideos/uso terapéutico , Dolor de la Región Lumbar/terapia , Mesoterapia , Adulto , Colchicina/análogos & derivados , Colchicina/uso terapéutico , Servicio de Urgencia en Hospital , Femenino , Humanos , Desplazamiento del Disco Intervertebral/complicaciones , Cetoprofeno/uso terapéutico , Lidocaína/uso terapéutico , Dolor de la Región Lumbar/etiología , Masculino , Persona de Mediana Edad , Piroxicam/análogos & derivados , Piroxicam/uso terapéutico , Estudios Prospectivos , Escala Visual AnalógicaRESUMEN
Major depressive disorder (MDD) is associated with alterations in calcium (Ca) and magnesium (Mg), as well as circulating pro- and anti-inflammatory cytokines. Anti-inflammatory drugs are commonly used as adjuvant treatments for MDD. However, no studies examined the effects of a combinatorial treatment with sertraline and ketoprofen, an anti-inflammatory drug, on Ca and Mg levels in MDD. The present study examined a) differences in both cations between drug-naïve MDD patients and controls, and b) the effects of sertraline and ketoprofen on Ca and Mg (both total and ionized). In the same patients, we also examined the associations between both cations and IL-1ß, IL-4, IL-6, IL-18, IFN-γ, TGF-ß1, zinc, and indoleamine 2,3-dioxygenase (IDO). Clinical improvement was assessed using the Beck Depression Inventory-II (BDI-II) at baseline and after follow up for 2 months. Serum Ca and Mg (total and ionized) were significantly lower in MDD patients as compared with controls, while treatment significantly increased calcium but decreased magnesium levels. There were significant and inverse correlations between the BDI-II scores from baseline to endpoint and Ca (both total and ionized), but not Mg, levels. The effects of calcium on the BDI-II score remained significant after considering the effects of zinc, IDO and an immune activation z unit-weighted composite score based on the sum of all cytokines. There was a significant and inverse association between this immune activation index and calcium levels from baseline to endpoint. In conclusion, lowered levels of both cations play a role in the pathophysiology of major depression. Antidepressant-induced increases in Ca are associated with clinical efficacy and attenuation of the immune response. The suppressant effect of antidepressants on Mg levels is probably a side effect of those drugs. New antidepressant treatments should be developed that increase the levels both Ca and Mg. Graphical abstract.
Asunto(s)
Antidepresivos/uso terapéutico , Calcio/sangre , Trastorno Depresivo Mayor/sangre , Magnesio/sangre , Adulto , Trastorno Depresivo Mayor/tratamiento farmacológico , Femenino , Humanos , Cetoprofeno/uso terapéutico , Masculino , Persona de Mediana Edad , Sertralina/uso terapéutico , Resultado del TratamientoRESUMEN
INTRODUCTION: Acute musculoskeletal injuries are one of the most common painful presentation when admission to the emergency department. The aim of the study is to compare the tenoxicam mesotherapy with intravenous dexketoprofen in pain control in patients with acute musculoskeletal injury. METHODS: This parallel randomized controlled trial was conducted with the patients admitted to the emergency department with musculoskeletal injury. Intravenous dexketoprofen was administered to the control group, and mesotherapy treatment was performed to the other group. Differences between 10th, 30th, 60th and 120th minutes VAS scores and on the admission VAS score, clinically meaningful change in pain intensity, and adverse effect of the procedures were compared among groups. THE RESULTS: The differences in VAS scores and the presence of clinically meaningful change in pain intensity were statistically significantly higher in mesotherapy group than the systemic therapy group in all time periods. During one-week follow-up period, there was no reported adverse effect neither in mesotherapy group nor in the systemic therapy group. CONCLUSIONS: The mesotherapy treatment may be superior than the systemic therapy for pain relief in musculoskeletal injury in short term follow-up in emergency department settings.
Asunto(s)
Antiinflamatorios no Esteroideos/administración & dosificación , Cetoprofeno/análogos & derivados , Mesoterapia , Dolor Musculoesquelético/tratamiento farmacológico , Piroxicam/análogos & derivados , Trometamina/administración & dosificación , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Antiinflamatorios no Esteroideos/uso terapéutico , Servicio de Urgencia en Hospital , Femenino , Estudios de Seguimiento , Humanos , Inyecciones Intravenosas , Cetoprofeno/administración & dosificación , Cetoprofeno/uso terapéutico , Masculino , Persona de Mediana Edad , Piroxicam/administración & dosificación , Piroxicam/uso terapéutico , Estudios Prospectivos , Resultado del Tratamiento , Trometamina/uso terapéutico , Adulto JovenRESUMEN
BACKGROUND: Previous studies have demonstrated the analgesic effects of ginger in different conditions, but evidence about its efficacy in migraine treatment is scarce. OBJECTIVE: This study aimed to evaluate the potential of ginger to improve acute migraine as an add-on strategy to standard treatment. METHODS: A double-blind placebo-controlled randomized clinical trial in the emergency room of a general hospital was conducted. Patients who sought medical care at the time of migraine attack were enrolled in this study. Only adults with episodic migraine (one to six migraine attacks per month) with or without aura were included. Sixty participants were randomized into two groups in which they received 400 mg of ginger extract (5% active ingredient) or placebo (cellulose), in addition to an intravenous drug (100 mg of ketoprofen) to treat the migraine attack. Patients filled a headache diary before, 0.5 h, 1 h, 1.5 h and 2 h after the medication. Pain severity, functional status, migraine symptoms and treatment satisfaction were also recorded. RESULTS: Patients treated with ginger showed significantly better clinical response after 1 h ( p = 0.04), 1.5 h ( p = 0.01) and 2 h ( p = 0.04). Furthermore, ginger treatment promoted reduction in pain and improvement on functional status at all times assessed. CONCLUSIONS: The addition of ginger to non-steroidal anti-inflammatory drugs may contribute to the treatment of migraine attack. This trial is registered at ClinicalTrials.gov (NCT02568644).
Asunto(s)
Analgésicos/uso terapéutico , Trastornos Migrañosos/tratamiento farmacológico , Extractos Vegetales/uso terapéutico , Zingiber officinale , Adulto , Antiinflamatorios no Esteroideos/uso terapéutico , Método Doble Ciego , Quimioterapia Combinada/métodos , Femenino , Humanos , Cetoprofeno/uso terapéutico , Masculino , Persona de Mediana EdadRESUMEN
TITLE: Sindrome de vasoconstriccion cerebral reversible tras abandono de habito tabaquico y tratamiento con bupropion.
Asunto(s)
Bupropión/efectos adversos , Arterias Cerebrales/efectos de los fármacos , Trastornos Cerebrovasculares/etiología , Cefaleas Primarias/etiología , Agentes para el Cese del Hábito de Fumar/efectos adversos , Cese del Hábito de Fumar , Síndrome de Abstinencia a Sustancias/etiología , Apraxias/etiología , Bupropión/uso terapéutico , Bloqueadores de los Canales de Calcio/uso terapéutico , Estenosis Carotídea/complicaciones , Arterias Cerebrales/diagnóstico por imagen , Trastornos Cerebrovasculares/inducido químicamente , Trastornos Cerebrovasculares/tratamiento farmacológico , Trastornos Cerebrovasculares/fisiopatología , Sustitución de Medicamentos , Femenino , Trastornos Neurológicos de la Marcha/etiología , Humanos , Cetoprofeno/análogos & derivados , Cetoprofeno/uso terapéutico , Angiografía por Resonancia Magnética , Imagen por Resonancia Magnética , Persona de Mediana Edad , Neuroimagen , Nimodipina/uso terapéutico , Trastornos de la Personalidad/etiología , Agentes para el Cese del Hábito de Fumar/uso terapéutico , Síndrome de Abstinencia a Sustancias/tratamiento farmacológico , Síndrome de Abstinencia a Sustancias/fisiopatología , Cefalea de Tipo Tensional/complicaciones , Trometamina/uso terapéutico , Vasoconstricción/efectos de los fármacosRESUMEN
BACKGROUND: Complex anesthesia is increasingly used in order to reduce postoperative pain and accelerate rehabilitation. The aim of this study was to evaluate the efficacy and safety of preemptive local anesthesia combined with general or spinal anesthesia in ankle arthroscopy. METHODS: From January 2014 to February 2016, 80 ankle anterior arthroscopies were performed. Patients were randomly assigned to one of 4 groups, depending on the type of anesthesia: A, general and local preemptive; B, spinal and local preemptive; C, general and placebo; D, spinal and placebo. After general or spinal anesthesia, each patient randomly received an injection of 7 mL of a mixture of local anesthetics or the same amount of normal saline. After 2, 4, 8, 12, 16, 24, 48, and 72 hours following the release of the tourniquet, the pain intensity level was measured with a visual analog scale (VAS). The use of additional analgesics and any adverse effects were also noted. RESULTS: Preemptive local anesthesia (groups A and B) resulted in a significantly lower level of pain intensity during the first 24 hours after surgery. Until 8 hours after the release of the tourniquet, the pain intensity level was statistically lower in the groups A, B, and D in comparison to C. During hospitalization, none of the patients from groups A and B received on-demand ketoprofen intravenously. No side effects of local anesthetic agents were observed. Two patients had transient numbness and paresthesia in the field of sensory nerve innervation of the dorsal intermediate cutaneous nerve of the foot. CONCLUSION: Preemptive operative site infiltration with a mixture of local anesthetics performed in ankle arthroscopy was a safe procedure. It reduced the level of intensity of postoperative pain and the amount of analgesics used. LEVEL OF EVIDENCE: Level I, prospective randomized study.
Asunto(s)
Anestesia Local , Anestésicos Locales/administración & dosificación , Artroscopía , Dolor Postoperatorio/prevención & control , Adulto , Anestesia General , Anestesia Raquidea , Tobillo , Antiinflamatorios no Esteroideos/uso terapéutico , Bupivacaína/administración & dosificación , Femenino , Humanos , Inyecciones , Cetoprofeno/uso terapéutico , Lidocaína/administración & dosificación , Masculino , Dimensión del Dolor , Dolor Postoperatorio/tratamiento farmacológicoRESUMEN
AIM: To assess the effect of sedation and local anaesthesia (LA) at disbudding, and the addition of meloxicam or ketoprofen treatment, on weight gain in dairy calves following disbudding. METHODS: Friesian-Jersey cross calves, from four dairy farms, were enrolled when 3-6 weeks old. All calves (n=271) were disbudded by veterinary personnel and randomly assigned to six groups: 136 were disbudded without sedation or LA, of which 31 received 20 mg meloxicam S/C and 75 received 150 mg ketoprofen I/M. A further 135 were disbudded with sedation (0.25 mg/kg xylazine I/M) and LA, of which 30 also received meloxicam and 75 received ketoprofen. Calves were weighed 3 days before, and 15 and 30 days after, disbudding (Day 0). Daily weight gain was analysed using mixed models and ANOVA. RESULTS: Complete results were obtained from 263 calves. From Day -3 to Day 15, the growth rate of calves disbudded without pain relief (0.53 (95% CI=0.47-0.60) kg/day) was less that of calves disbudded with some form of pain relief (0.65 (95% CI=0.62-0.68) kg/d; p=0.004). There was no difference between the effect of meloxicam or ketoprofen (p=1.00). An interaction between use of sedation and LA and additional non-steroidal anti-inflammatory drugs (NSAID) meant that NSAID treatment did not increase growth rates in calves disbudded with sedation and LA but did increase growth rates for calves disbudded without pain relief (p<0.05). From Day 16 to Day 30 there was no effect of NSAID treatment on growth rate, but calves receiving LA and sedation grew faster (0.74 (95% CI=0.69-0.80) kg/day) than calves disbudded without LA and sedation (0.66 (95% CI=0.61-0.71) kg/day; p=0.018). From Day -3 to Day 30, calves disbudded with sedation and LA grew faster (0.71 (95%CI=0.64-0.77) kg/day) than calves disbudded without sedation and LA (0.60 (95% CI=0.55-0.65) kg/day; p=0.011). However, addition of NSAID to sedation and LA made no further difference to growth rates (p=0.69). CONCLUSIONS: Dairy calves disbudded with no pain relief had slower growth rates than calves receiving pain relief. From Day 15 to 30 calves given no pain relief, or NSAID alone, grew more slowly than those receiving sedation and LA at disbudding. The addition of NSAID treatment to sedation and LA did not further increase growth rates. CLINICAL RELEVANCE: This study adds to the evidence that pain management when disbudding is beneficial for calf productivity as well as calf welfare.
Asunto(s)
Anestesia Local/veterinaria , Antiinflamatorios no Esteroideos/uso terapéutico , Bovinos/crecimiento & desarrollo , Cuernos/cirugía , Hipnóticos y Sedantes/uso terapéutico , Anestesia Local/métodos , Animales , Bovinos/cirugía , Sedación Consciente/métodos , Sedación Consciente/veterinaria , Industria Lechera/métodos , Femenino , Cetoprofeno/uso terapéutico , Meloxicam , Tiazinas/uso terapéutico , Tiazoles/uso terapéutico , Aumento de Peso , Xilazina/uso terapéuticoRESUMEN
The combination of pomegranate seed oil and ketoprofen in nanoemulsions aiming to improve the antinociceptive effect was evaluated according to the writhing test and Complete Freud's Adjuvant induced paw inflammation in mice. The formulations showed adequate characteristics and improved ketoprofen's photostability against UVC radiation exposure. The dialysis bag technique showed that 100% of the drug was released from the nanoemulsions after 3h and the oil amount had no influence on the releasing. Furthermore, time- and dose-response curves were obtained to determine the antinociceptive effect of the formulations. In the post-test, the nanoemulsion containing ketoprofen significantly reduced abdominal constrictions in time-response curve, showing effect up to 12h while the free ketoprofen showed effect up to 3h. In addition, the blank nanoemulsion presented a reduction of abdominal constriction up to 1h of pre-treatment. Regarding the dose-response curve, the free ketoprofen presents effect at 0.5mg/Kg dose and nanoemulsion at 1.0mg/Kg dose. Time- and dose-response curves were performed to determine the antinociceptive effect in inflammatory pain. After the evaluation of mechanical allodynia testing at the Von Frey Hair, the free ketoprofen showed effect up to 6h while nanoemulsions presented effect up to 10h. Moreover, acute toxicity was performed with ALT and AST activity evaluations and urea levels. After 7 days of treatment, no toxic effects for nanoemulsions were found. In conclusion, ketoprofen-loaded pomegranate seed oil nanoemulsions presented adequate characteristics and a high antinociceptive activity in the animal models tested.
Asunto(s)
Analgésicos/uso terapéutico , Antiinflamatorios no Esteroideos/uso terapéutico , Emulsiones/química , Lythraceae/química , Nanopartículas/química , Aceites de Plantas/uso terapéutico , Rayos Ultravioleta , Abdomen/patología , Ácido Acético , Analgésicos/administración & dosificación , Analgésicos/farmacología , Animales , Antiinflamatorios no Esteroideos/administración & dosificación , Antiinflamatorios no Esteroideos/farmacología , Constricción Patológica , Liberación de Fármacos , Estabilidad de Medicamentos , Adyuvante de Freund , Inflamación/complicaciones , Inflamación/tratamiento farmacológico , Inyecciones , Cetoprofeno/administración & dosificación , Cetoprofeno/farmacología , Cetoprofeno/uso terapéutico , Masculino , Ratones , Actividad Motora/efectos de los fármacos , Dolor/complicaciones , Dolor/tratamiento farmacológico , Aceites de Plantas/administración & dosificación , Aceites de Plantas/farmacología , Semillas/química , Pruebas de Toxicidad AgudaRESUMEN
No disponible
Asunto(s)
Humanos , Femenino , Adulto , Accidente Cerebrovascular/complicaciones , Accidente Cerebrovascular/diagnóstico , Disección de la Arteria Vertebral/complicaciones , Disección de la Arteria Vertebral , Ejercicios de Estiramiento Muscular/efectos adversos , Ejercicios de Estiramiento Muscular/métodos , Yoga , Fuerza Muscular/fisiología , Contracción Muscular , Hipoestesia/complicaciones , Hipoestesia/patología , Hipoestesia , Cetoprofeno/uso terapéutico , Dolor de Cuello/complicaciones , Oxígeno/uso terapéutico , Angiografía/métodosRESUMEN
PURPOSE: The effect of a single-dose of pre-emptive pregabalin is still unknown, although it is used as an adjuvant in controlling acute postoperative pain. The purpose of this study was to evaluate the effects of pre-emptive single-dose pregabalin on postoperative acute pain and 24-hour opioid consumption in patients who underwent double-jaw surgery. PATIENTS AND METHODS: Forty patients (18 to 45 yr old; American Society of Anesthesiologists status I to II) for whom elective double-jaw surgery was planned under general anesthesia were included in this study, which had been planned as a prospective, randomized, and double-blinded study. Patients were randomly divided into 2 groups: the pregabalin group (n = 20) was given pregabalin 150 mg orally 1 hour before general anesthesia and the placebo group (n = 20) was given an oral placebo capsule. The groups were administered the routine general anesthesia protocol. Postoperative analgesia was performed intravenously in the 2 groups twice a day with dexketoprofen trometamol 50 mg and patient-controlled analgesia with fentanyl. Postoperative analgesia was evaluated using the visual analog scale (VAS). Fentanyl consumption, additional analgesia requirement, and side-effects were recorded during the first 24 hours after surgery. Descriptive and bivariate statistics were computed, and significance was set at a P value less than .05. RESULTS: Compared with placebo, the VAS score was statistically lower in the pregabalin group during the early postoperative period (P < .05). The 24-hour opioid consumption was significantly higher in the placebo group compared with the pregabalin group (509.40 ± 261.56 vs. 260.10 ± 246.53 µq, respectively; P = .004). In addition, the analgesia requirement was statistically lower in the pregabalin group (P < .05). Nausea or vomiting was observed more often in the placebo group, whereas other side-effects were similar for the 2 groups. CONCLUSION: A single 150-mg dose of pre-emptive pregabalin decreased postoperative opioid consumption in the first 24 hours after double-jaw surgery. Multimodal analgesia techniques that contain pre-emptive analgesia can be used successfully in preventing postoperative pain caused by orthognathic surgery.
Asunto(s)
Analgésicos/uso terapéutico , Narcóticos/uso terapéutico , Procedimientos Quirúrgicos Ortognáticos/métodos , Dolor Postoperatorio/prevención & control , Pregabalina/uso terapéutico , Premedicación , Adolescente , Adulto , Analgesia Controlada por el Paciente/métodos , Analgésicos/administración & dosificación , Antiinflamatorios no Esteroideos/uso terapéutico , Método Doble Ciego , Femenino , Fentanilo/administración & dosificación , Fentanilo/uso terapéutico , Estudios de Seguimiento , Humanos , Cetoprofeno/análogos & derivados , Cetoprofeno/uso terapéutico , Masculino , Persona de Mediana Edad , Narcóticos/administración & dosificación , Osteotomía Le Fort/métodos , Osteotomía Sagital de Rama Mandibular/métodos , Dimensión del Dolor/métodos , Placebos , Náusea y Vómito Posoperatorios/etiología , Pregabalina/administración & dosificación , Estudios Prospectivos , Trometamina/uso terapéutico , Adulto JovenRESUMEN
El abordaje laparoscópico es el tratamiento de elección para la cirugía de vesícula, sin embargo, algunos pacientes requieren una conversión de la técnica, lo que origina en ellos un dolor postoperatorio moderado-severo. Tradicionalmente los opioides han sido utilizados para tratar dicho dolor, pero sus efectos secundarios han llevado a la búsqueda de nuevas alternativas (administración de anestésicos locales en plexos, fascias, nervios o herida). Presentamos 4 casos clínicos a los que se realizó el bloqueo ecoguiado de las ramas cutáneas de los nervios intercostales en la línea axilar media de T6 a T12 con levobupivacaína como alternativa analgésica en cirugía abierta de vesícula, con unos buenos resultados (AU)
Laparoscopic cholecystectomy has become the standard treatment for gallbladder diseases. However, there are still some patients for whom conversion to open surgery is required. This surgery can produce significant post-operative pain. Opioids drugs have traditionally been used to treat this pain, but side effects have led to seeking alternatives (plexus, nerve or fascia blocks or wound). The cases are presented of 4 patients subjected to ultrasound-guided intercostal branches blocks in the mid-axillary line from T6 to T12 with levobupivacaine as an analgesic alternative in open surgery of gallbladder, with satisfactory results (AU)
Asunto(s)
Anciano de 80 o más Años , Anciano , Femenino , Humanos , Masculino , Bloqueo de Rama/tratamiento farmacológico , Bloqueo de Rama/terapia , Nervios Intercostales , Colecistectomía/métodos , Dolor Postoperatorio/complicaciones , Dolor Postoperatorio/tratamiento farmacológico , Bupivacaína/uso terapéutico , Vesícula Biliar , Vesícula Biliar , Vesícula Biliar/patología , Vesícula Biliar/cirugía , Síndrome Poscolecistectomía/complicaciones , Síndrome Poscolecistectomía/tratamiento farmacológico , Acetaminofén/uso terapéutico , Cetoprofeno/uso terapéutico , Anestesia LocalRESUMEN
OBJECTIVE: Comparison of dexketoprofen and paracetamol added to the lidocaine in Regional Intravenous Anesthesia in terms of hemodynamic effects, motor and sensorial block onset times, intraoperative VAS values, and analgesia requirements. METHOD: The files of 73 patients between 18 and 65 years old in the ASA I-II risk group who underwent hand and forearm surgery were analyzed and 60 patients were included in the study. Patients were divided into 3 groups: Group D (n = 20), 3 mg/kg 2% lidocaine and 50 mg/2 mL dexketoprofen trometamol; Group P (n = 20), 3 mg/kg 2% lidocaine and 3 mg/kg paracetamol; Group K (n = 20), 3 mg/kg 2% lidocaine. Demographic data, motor and sensorial block times, heart rate, mean blood pressure, VAS values, and intraoperative and postoperative analgesia requirements were recorded. RESULTS: Sensorial and motor block onset durations of Group K were significantly longer than other groups. Motor block termination duration was found to be significantly longer in Group D than in Group K. VAS values of Group K were found higher than other groups. There was no significant difference in VAS values between Group D and Group P. Analgesia requirement was found to be significantly more in Group K than in Group P. There was no significant difference between the groups in terms of heart rates and mean arterial pressures. CONCLUSION: We concluded that the addition of 3 mg/kg paracetamol and 50 mg dexketoprofen to lidocaine as adjuvant in Regional Intravenous Anesthesia applied for hand and/or forearm surgery created a significant difference clinically.
Asunto(s)
Acetaminofén , Anestesia de Conducción/métodos , Anestesia Intravenosa/métodos , Cetoprofeno/análogos & derivados , Lidocaína , Trometamina , Acetaminofén/administración & dosificación , Acetaminofén/uso terapéutico , Adulto , Femenino , Antebrazo/cirugía , Humanos , Cetoprofeno/administración & dosificación , Cetoprofeno/uso terapéutico , Lidocaína/administración & dosificación , Lidocaína/uso terapéutico , Masculino , Dimensión del Dolor , Trometamina/administración & dosificación , Trometamina/uso terapéutico , Adulto JovenRESUMEN
OBJECTIVE: To study the efficacy and safety of artrosilene in the combination with piascledine in patients with low-back pain. METHODS: Sixty patients, 42 women and 18 men (mean age 53,6±10,4 years) with chronic nonspecific low-back pain were treated with artrosilene (ketoprofen lysine salt) in the combination with the chondro protector piascledine (a mix of avocado and soybean oil extracts). RESULTS: There the persistent decrease in the intensity of pain syndrome and severity of vertebral syndrome and improvement of quality of life. CONCLUSIONS: The drugs can be recommended for treatment of nonspecific low-back pain.
Asunto(s)
Antiinflamatorios no Esteroideos/uso terapéutico , Cetoprofeno/análogos & derivados , Dolor de la Región Lumbar/tratamiento farmacológico , Lisina/análogos & derivados , Fitosteroles/uso terapéutico , Extractos Vegetales/uso terapéutico , Vitamina E/uso terapéutico , Adulto , Antiinflamatorios no Esteroideos/efectos adversos , Combinación de Medicamentos , Quimioterapia Combinada , Femenino , Humanos , Cetoprofeno/efectos adversos , Cetoprofeno/uso terapéutico , Dolor de la Región Lumbar/diagnóstico , Dolor de la Región Lumbar/fisiopatología , Lisina/efectos adversos , Lisina/uso terapéutico , Masculino , Persona de Mediana Edad , Fitosteroles/efectos adversos , Extractos Vegetales/efectos adversos , Resultado del Tratamiento , Vitamina E/efectos adversosRESUMEN
Piascledine is a plant drug which positively influences the metabolism of cartilage and bone tissues. The authors studied the therapeutic effect of the drug in outpatients with chronic nonspecific dorsalgia. Piascledine was administered in dose 300 mg daily during two months. In the first month, it was used in the combination with artrosilene (320 mg daily). A comparison group included patients receiving monotherapy with NSAIDs (artrosilene). The study confirmed the high analgesic efficacy of piascledine in the treatment of patients with chronic nonspecific dorsalgia with controlled using of NSAIDs. The positive effect of piascledine was demonstrated after one month of treatment. The authors suggest that further clinical trials and placebo-control studies are needed to confirm these results.
Asunto(s)
Dolor de Espalda/tratamiento farmacológico , Fitosteroles/uso terapéutico , Extractos Vegetales/uso terapéutico , Vitamina E/uso terapéutico , Antiinflamatorios no Esteroideos/administración & dosificación , Antiinflamatorios no Esteroideos/uso terapéutico , Combinación de Medicamentos , Femenino , Humanos , Cetoprofeno/administración & dosificación , Cetoprofeno/análogos & derivados , Cetoprofeno/uso terapéutico , Lisina/administración & dosificación , Lisina/análogos & derivados , Lisina/uso terapéutico , Masculino , Persona de Mediana Edad , Fitosteroles/administración & dosificación , Extractos Vegetales/administración & dosificación , Vitamina E/administración & dosificaciónRESUMEN
OBJECTIVE: The aim of the present study was to evaluate the combination therapy of an antibiotic (enrofloxacine-arginine, Baytril® RSi) and a non-steroidal anti-inflammatory drug (NSAID, ketoprofen, Dinalgen® 60 mg/ml) against a Haemophilus parasuis (HPS) infection in nursery piglets. MATERIAL AND METHODS: Forty-eight 3-week-old pigs were divided into four groups (group 1: non-infected controls; group 2: HPS infection; group 3: HPS infection/Baytril® RSi; group 4: HPS infection/Baytril® RSi/Dinalgen®) and housed within the isolation facility. After an acclimatization period of 10 days, the piglets in groups 2-4 were intratracheally infected with 1 x 107 colony forming units (CFU) HPS serovar 5, whereas animals of group 1 received physiological saline. Total clinical scores and joint scores were calculated daily after clinical examination. Seven days after the infection, piglets were humanely euthanized. At necropsy, pathological findings on serosal surfaces were scored according to severity and extension. RESULTS: Group 1 had the lowest clinical and pathological scores, followed by groups 4, 3 and 2. Piglets treated with the combination of an antibiotic and an NSAID showed the lowest body temperatures (significant). The average daily weight gain (ADWG) was not significantly different between the groups, but piglets of group 4 tended to reach a higher mean ADWG (340.5 g/d) than animals of the non-infected group 1 (323.8 g/d), the Baytril® RSi-treated group 3 (278.0 g/d) and the positive control group 2 (247.0 g/d). Piglets of the positive control group (group 2) achieved the highest values in the clinical, joint and serositis scores. CONCLUSION: The study demonstrated that a simultaneous treatment with enrofloxacine-arginine (Baytril® RSi) and ketoprofen had a superior therapeutic effect compared to a single antibiotic treatment with Baytril® RSi in nursery piglets experimentally infected with HPS.
Asunto(s)
Antibacterianos/uso terapéutico , Antiinflamatorios no Esteroideos/uso terapéutico , Infecciones por Haemophilus/veterinaria , Haemophilus parasuis/aislamiento & purificación , Enfermedades de los Porcinos/tratamiento farmacológico , Enfermedades de los Porcinos/microbiología , Animales , Animales Recién Nacidos , Temperatura Corporal , Enrofloxacina , Fluoroquinolonas/uso terapéutico , Infecciones por Haemophilus/tratamiento farmacológico , Infecciones por Haemophilus/microbiología , Cetoprofeno/uso terapéutico , Sus scrofa , PorcinosRESUMEN
The purpose of this study was to evaluate the efficacy of an oral solution of ketoprofen administered in drinking water at a lower dose as a complement to antimicrobial therapy in a mild outbreak of porcine respiratory disease complex. The study was performed with 120 pigs with rectal temperature between 39.9 and 41°C and at least 1 sign indicating porcine respiratory disease complex (dyspnea, cough, nasal discharge, or depression). Animals were randomly allocated in 2 groups (treated and control group). Animals in both groups received etiological therapy with doxycycline at 10 mg · kg(-1) in drinking water for 5 d. The animals in the treated group also received 1.5 mg · kg(-1) of ketoprofen during the first 3 d. The reduction in rectal temperature in the treated group was significantly greater during the days of ketoprofen administration and up to 1 d after the end of treatment (P < 0.05). The percentage of dyspneic animals was significantly less (P < 0.05) in the treated group from d 2 to 5 of the study. Also, a significant improvement regarding depression and cough was seen in the animals of the treated group. No statistically significant (P > 0.05) differences were evidenced in productive variables. In conclusion, oral treatment with ketoprofen at 1.5 mg · kg(-1) in combination with antimicrobial therapy was found to be a clinically effective approach in outbreaks of mild porcine respiratory disease complex.
Asunto(s)
Antiinflamatorios no Esteroideos/uso terapéutico , Cetoprofeno/uso terapéutico , Síndrome Respiratorio y de la Reproducción Porcina/tratamiento farmacológico , Administración Oral , Animales , Antiinfecciosos/uso terapéutico , Doxiciclina/uso terapéutico , Agua Potable , Quimioterapia Combinada/veterinaria , Femenino , Masculino , Síndrome Respiratorio y de la Reproducción Porcina/virología , Porcinos , Factores de TiempoRESUMEN
INTRODUCTION: Management of the perioperative hemorrhagic risk is of major interest in patients undergoing total arthroplasty of the lower limb. Anemia in the postoperative period of that increasingly performed surgery carries its own morbidity and mortality. Better anticipation of its occurrence could be done with a refined knowledge of bleeding kinetics. PATIENTS AND METHODS: We conducted a retrospective study in a single centre on 451 consecutive patients undergoing elective unilateral primary total hip or knee arthroplasty for osteoarthritis. Volume of total blood loss according to Mercuriali's formula and variations of haemoglobin levels were calculated between day 0 (D0) and postoperative day 8 (D8), and during subdivided periods between D0-D1, D1-D3 and D3-D8. Frequency and volume of autologous and homologous blood transfusions were also analyzed. Comparisons were done taking into account the use of intraoperative tranexemic acid (TA). RESULTS: Seventy to 75% of blood loss occurred between D0 and D1. Bleeding occurred mostly between the end of surgery and morning of D1, and tended to stop at D3. TA significantly reduced blood loss in the first 3days, mostly after knee prosthesis surgery. However, the bleeding kinetics were the same with or without TA. CONCLUSION: Loss of haemoglobin occurred mostly in the early postoperative period. To avoid transfusion delays, haemoglobin levels should be monitored regularly until the third postoperative day after total arthroplasty, especially when D1 haemoglobin is close to the transfusion threshold. Furthermore, our results support the routine use of TA.